CDK4 and breast carcinoma: Another CDK4/6 inhibitor-based immunotherapy combination (palbociclib plus pembrolizumab) in a Phase II study in postmenopausal patients with metastatic ER+ breast cancer patients (NCT02778685) also demonstrated a prolonged median follow-up time of 13.7 months and increased partial response rate of 42.1% (62).